Deliberations with American Indian and Alaska Native People about the Ethics of Genomics: An Adapted Model of Deliberation Used with Three Tribal Communities in the United States

AJOB Empirical Bioethics
Volume 12, 2020 Issue 3
https://www.tandfonline.com/toc/uabr21/current

 

Article
Deliberations with American Indian and Alaska Native People about the Ethics of Genomics: An Adapted Model of Deliberation Used with Three Tribal Communities in the United States
Erika Blacksher, Vanessa Y. Hiratsuka, Jessica W. Blanchard, Justin R. Lund, Justin Reedy, Julie A. Beans, Bobby Saunkeah, Micheal Peercy, Christie Byars, Joseph Yracheta, Krystal S. Tsosie, Marcia O’Leary, Guthrie Ducheneaux & Paul G. Spicer
Pages: 164-178
Published online: 14 Jun 2021

Transgenerational Trauma

AMA Journal of Ethics
Volume 23, Number 6: E435-504 June 2021
https://journalofethics.ama-assn.org/issue/transgenerational-trauma

 

Transgenerational Trauma
One thing that makes trauma transgenerational is narrative. Narrative, for example, is what makes a Confederate flag from 1865 flint for insurrection in 2021. Consequences of global and domestic insults, such as slavery and forced migration, have long ramified intergenerationally in communities, families, and individuals’ bodies. Legacies of trauma travel in stories across places and over time, and their effects include health status inequity and cumulative stress embodiment. Transmission of historically entrenched patterns of oppression also influence persons’ lived experiences of marginalization, convey health risk, and can play out during clinical encounters.

What do we want from Explainable Artificial Intelligence (XAI)? – A stakeholder perspective on XAI and a conceptual model guiding interdisciplinary XAI research

Artificial Intelligence – An International Journal
Volume 296 July 2021
https://www.sciencedirect.com/journal/artificial-intelligence/vol/296/suppl/C

 

Research article Abstract only
What do we want from Explainable Artificial Intelligence (XAI)? – A stakeholder perspective on XAI and a conceptual model guiding interdisciplinary XAI research
Markus Langer, Daniel Oster, Timo Speith, Holger Hermanns, … Kevin Baum
Article 103473

A realist systematic review of evidence from low- and middle-income countries of interventions to improve immunization data use

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 10 Jul 2021)

 

A realist systematic review of evidence from low- and middle-income countries of interventions to improve immunization data use
The use of routine immunization data by health care professionals in low- and middle-income countries remains an underutilized resource in decision-making. Despite the significant resources invested in develop…
Authors: Allison L. Osterman, Jessica C. Shearer and Nicole A. Salisbury
Citation: BMC Health Services Research 2021 21:672
Content type: Research
Published on: 8 July 2021

The burden of hand, foot, and mouth disease among children under different vaccination scenarios in China: a dynamic modelling study

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 10 Jul 2021)

 

The burden of hand, foot, and mouth disease among children under different vaccination scenarios in China: a dynamic modelling study
Hand, foot, and mouth disease (HFMD) is a common illness in young children. A monovalent vaccine has been developed in China protecting against enterovirus-71, bivalent vaccines preventing HFMD caused by two v…
Authors: Zhixi Liu, Jie Tian, Yue Wang, Yixuan Li, Jing Liu-Helmersson, Sharmistha Mishra, Abram L. Wagner, Yihan Lu and Weibing Wang
Citation: BMC Infectious Diseases 2021 21:650
Content type: Research
Published on: 5 July 2021

Effectiveness of a community-level social mobilization intervention in achieving the outcomes of polio vaccination campaigns during the post-polio-endemic period: Evidence from CORE Group polio project in Uttar Pradesh, India

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 10 Jul 2021)

 

Effectiveness of a community-level social mobilization intervention in achieving the outcomes of polio vaccination campaigns during the post-polio-endemic period: Evidence from CORE Group polio project in Uttar Pradesh, India
A social mobilization (SM) initiative contributed to India’s success in polio elimination. This was the CORE Group Polio Project (CGPP) India, a partner of the Uttar Pradesh (UP) SM Network and which continued…
Authors: Manojkumar Choudhary, Roma Solomon, Jitendra Awale, Rina Dey, Jagajeet Prasad Singh and William Weiss
Citation: BMC Public Health 2021 21:1371
Content type: Research article
Published on: 10 July 2021

The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015–2018

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 10 Jul 2021)

 

The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015–2018
Adverse events following immunization is an important factor influencing public trust in vaccination. Publicizing its incidence timely can increase public trust. The aim of this study is to describe the incide…
Authors: Ran Hu, Shanshan Peng, Yuanbao Liu, Fengyang Tang, Zhiguo Wang, Lei Zhang, Jun Gao and Hongxiong Guo
Citation: BMC Public Health 2021 21:1338
Content type: Research
Published on: 7 July 2021

COVID-19 outbreaks among isolated Amazonian indigenous people, Ecuador

Bulletin of the World Health Organization
Volume 99, Number 7, July 2021, 477-540
https://www.ncbi.nlm.nih.gov/pmc/issues/384766/

 

Editorials
COVID-19 outbreaks among isolated Amazonian indigenous people, Ecuador
Aquiles R Henriquez-Trujillo, Esteban Ortiz-Prado, Ismar A Rivera-Olivero, Nemonte Nenquimo, Andrés Tapia, Mitchell Anderson, Tannya Lozada, Miguel Angel Garcia-Bereguiain
Bull World Health Organ. 2021 Jul 1; 99(7): 478–478A. Published online 2021 Jul 1. doi: 10.2471/BLT.20.283028
PMCID: PMC8243033

Vaccine manufacturing capacity in low- and middle-income countries

Bulletin of the World Health Organization
Volume 99, Number 7, July 2021, 477-540
https://www.ncbi.nlm.nih.gov/pmc/issues/384766/

 

Vaccine manufacturing capacity in low- and middle-income countries
Mohammed Imran Khan, Aamer Ikram, Hasan Bin Hamza
Bull World Health Organ. 2021 Jul 1; 99(7): 479–479A. Published online 2021 Jul 1. doi: 10.2471/BLT.20.273375
PMCID: PMC8243032

National focal points and implementation of the International Health Regulations

Bulletin of the World Health Organization
Volume 99, Number 7, July 2021, 477-540
https://www.ncbi.nlm.nih.gov/pmc/issues/384766/

 

Perspectives
National focal points and implementation of the International Health Regulations
Kumanan Wilson, Sam Halabi, Helge Hollmeyer, Lawrence O Gostin, David P Fidler, Corinne Packer, Lindsay Wilson, Ronald Labonté
Bull World Health Organ. 2021 Jul 1; 99(7): 536–538. Published online 2021 May 4. doi: 10.2471/BLT.20.270116
PMCID: PMC8243029

Human population history at the crossroads of East and Southeast Asia since 11,000 years ago

Cell
Jul 08, 2021 Volume 184 Issue 14 p3591-3842
https://www.cell.com/cell/current

 

Articles
Human population history at the crossroads of East and Southeast Asia since 11,000 years ago
Tianyi Wang, et al.
Genome-wide analysis of 31 ancient individuals from southern China (Guangxi and Fujian) reveals human population history at the crossroads of East and Southeast Asia from 500–11,000 years ago.
Highlights
Guangxi region in southern China had distinct East Asian ancestry 11 kya not found today
At least three distinct ancestries were in southern China and SE Asia prior to 10 kya
Three admixed ancestries were present in pre-agricultural Guangxi 9–6 kya
Tai-Kadai- and Hmong-Mien-related ancestry present in Guangxi by 1.5–0.5 kya

Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19

Clinical Pharmacology & Therapeutics
Volume 110, Issue 1 Pages: 1-262 July 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

 

Perspectives
Open Access
Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19
Paul Aliu, Séverine Sarp, Paige Fitzsimmons
Pages: 26-28
First Published:16 December 2020

Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement

Clinical Pharmacology & Therapeutics
Volume 110, Issue 1 Pages: 1-262 July 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

 

Reviews
White Paper
Open Access
Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement
Ahizechukwu C. Eke, Adeniyi Olagunju, Jeremiah Momper, Martina Penazzato, Elaine J. Abrams, Brookie M. Best, Edmund V. Capparelli, Adrie Bekker, Yodit Belew, Jennifer J. Kiser, Kimberly Struble, Graham Taylor, Catriona Waitt, Mark Mirochnick, Tim R. Cressey, Angela Colbers, on behalf of the participants of the WHO-IMPAACT workshop on “Approaches to Optimize and Accelerate Pharmacokinetic Studies in Pregnant and Lactating Women”
Pages: 36-48
First Published:15 September 2020

Demographic diversity of participants in Pfizer sponsored clinical trials in the United States

Contemporary Clinical Trials
Volume 106 July 2021
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/106/suppl/C

 

Research article Open access
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States
Melinda Rottas, Peter Thadeio, Rachel Simons, Raven Houck, … Rod MacKenzie
Article 106421 melinda.m.rottas@pfizer.com

Highlights
• Limited data have previously been reported regarding clinical trial diversity from drug sponsors.
• Race, ethnicity, gender, and age data for participants in Pfizer US trials initiated between 2011 and 2020 are summarized.
• The results establish a baseline of clinical trial diversity to measure improvement over time.
• Future analyses will allow exploration of factors leading to and arising from disparities in clinical trial participation.
Abstract
The approval of new medicinal agents requires robust efficacy and safety clinical trial data demonstrated to be applicable to population subgroups. Limited data have previously been reported by drug sponsors on the topic of clinical trial diversity. In order to establish a baseline of diversity in our clinical trials that can be used by us and other sponsors, an analysis of clinical trial diversity was conducted covering race, ethnicity, sex, and age. This analysis includes Pfizer interventional clinical trials that initiated enrollment between 2011 through 2020. The data set comprises 213 trials with 103,103 US participants. The analysis demonstrated that overall trial participation of Black or African American individuals was at the US census level (14.3% vs 13.4%), participation of Hispanic or Latino individuals was below US census (15.9% vs 18.5%), and female participation was at US census (51.1% vs 50.8%). The analysis also examined the percentage of trials that achieved racial and ethnic distribution levels at or above census levels. Participant levels above census were achieved in 56.1% of Pfizer trials for Black or African American participants, 51.4% of trials for White participants, 16.0% of trials for Asian participants, 14.2% of trials for Native Hawaiian and Pacific Islander participants, 8.5% of trials for American Indian and Alaska Native participants, and 52.3% of trials for Hispanic or Latino participants. The results presented here provide a baseline upon which we can quantify the impact of our ongoing efforts to improve racial and ethnic diversity in clinical trials.

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders’ Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

The European Journal of Public Health
SUPPLEMENT – Volume 31, Issue Supplement_1, July 2021
https://academic.oup.com/eurpub/issue/31/Supplement_1

 

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders’ Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions
Mental illness represents an enormous personal, social and societal burden for European citizens1 calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,2 and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications (‘eHealth’3 and ‘m-Health’4) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders5,6 and meta-analyses show effect sizes similar to face-to-face interventions.7

From Ebola to COVID-19: emergency preparedness and response plans and actions in Lagos, Nigeria

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 10 Jul 2021]

 

From Ebola to COVID-19: emergency preparedness and response plans and actions in Lagos, Nigeria
Authors: Akin Abayomi, Mobolanle R. Balogun, Munir Bankole, Aduragbemi Banke-Thomas, Bamidele Mutiu, John Olawepo, Morakinyo Senjobi, Oluwakemi Odukoya, Lanre Aladetuyi, Chioma Ejekam, Akinsanya Folarin, Madonna Emmanuel, Funke Amodu, Adesoji Ologun, Abosede Olusanya, Moses Bakare…
Content type: Commentary
9 July 2021

Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership – a qualitative study of policy actors’ views

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 10 Jul 2021]

 

Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership – a qualitative study of policy actors’ views
Authors: Belinda Townsend
Content type: Research
8 July 2021

July 2021 | Borders, Immigrants & Health

Health Affairs
Vol. 40, No. 7 July 2021
https://www.healthaffairs.org/toc/hlthaff/current

 

July 2021 | Borders, Immigrants & Health
About one in seven residents of the US is an immigrant, and about fifteen million people live within 100 kilometers of the US-Mexico border. Disparities in health status exist between people born in the US and those who have immigrated. Immigration policy has been contentious throughout US history, and current policies in the US and Mexico have significant effects on the health and well-being of tens of millions of people. This thematic issue of Health Affairs focuses on immigrants and borders. The overview article by Arturo Vargas Bustamante and coauthors describes a range of health policy issues raised by the continuously shifting demography of US immigrants.

Localisation and local humanitarian action

Humanitarian Exchange Magazine
Number 79, May 2021
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

 

Localisation and local humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies,  non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported.  Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 10 Jul 2021]

 

Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive re…
Authors: Musha Chen, Yue Yuan, Yiguo Zhou, Zhaomin Deng, Jin Zhao, Fengling Feng, Huachun Zou and Caijun Sun
Citation: Infectious Diseases of Poverty 2021 10:94
Content type: Scoping Review
Published on: 5 July 2021

Research ethics during a pandemic (COVID-19)

International Health
Volume 13, Issue 4, July 2021
https://academic.oup.com/inthealth/issue/13/4

 

COMMENTARIES
Research ethics during a pandemic (COVID-19)
Kheng-Wei Yeoh, Ketan Shah
The current pandemic with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a major global health crisis.1 This has put tremendous strain on healthcare systems around the world and naturally raises issues concerning the allocation of scarce resources. It presents a clear and urgent need for research into management of the disease in individuals and of the epidemic in populations. Addressing this need around the world raises practical and ethical issues for the scientific research…

Statement on Universal Affordable Vaccination against Coronavirus Disease covid-19, International Cooperation and Intellectual Property

International Human Rights Law Review
Volume 10 (2021): Issue 1 (Jun 2021)
https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml

 

Full Access
Statement on Universal Affordable Vaccination against Coronavirus Disease covid-19, International Cooperation and Intellectual Property
Committee on Economic, Social and Cultural Rights
Pages: 180–187
Online Publication Date: 31 May 2021
Abstract
Access to a vaccine against coronavirus disease (covid-19) that is safe, effective and based on the best scientific developments is an essential component of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health and the right of everyone to enjoy the benefits of scientific progress and its applications. States therefore have an obligation to take all the necessary measures, as a matter of priority and to the maximum of their available resources, to guarantee all persons access to vaccines against covid-19, without any discrimination. This statement builds on the previous statements of the Committee on Economic, Social and Cultural Rights of 6 April 2020 on the coronavirus disease (covid-19) pandemic and economic, social and cultural rights (E/C.12/2020/1) and of 27 November 2020 on universal and equitable access to vaccines for the coronavirus disease (covid-19) (E/C.12/2020/2). It is intended to remind States of their obligations under the International Covenant on Economic, Social and Cultural Rights in relation to universal access and affordability of vaccines against covid-19, particularly with regard to international cooperation and intellectual property

Data Resource Profile: The Copenhagen Hospital Biobank (CHB)

International Journal of Community Medicine and Public Health
Vol 8, No 5 (2021) May 2021
https://www.ijcmph.com/index.php/ijcmph/issue/view/76

 

Data Resource Profiles
Data Resource Profile: The Copenhagen Hospital Biobank (CHB)
Erik Sørensen, Lene Christiansen, Bartlomiej Wilkowski, Margit H Larsen, Kristoffer S Burgdorf
International Journal of Epidemiology, Volume 50, Issue 3, June 2021, Pages 719–720e, https://doi.org/10.1093/ije/dyaa157
lene.christiansen.02@regionh.dk
Extract
Every year thousands of blood samples are drawn from patients admitted to Danish hospitals for diagnostic and treatment purposes. Traditionally, the leftover blood will be discarded after the required laboratory analyses are completed. However, such residual blood samples can be highly valuable for biomedical research, given the vast amount of clinical information these samples are often accompanied by—directly from the electronic patient record or through linkage to medical registers. To this end the Copenhagen Hospital Biobank (CHB) was established, with the overall aim to facilitate research in health and disease by enabling researchers’ access to a large resource of well-defined patient samples.

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsA Randomized Clinical Trial

JAMA
July 6, 2021, Vol 326, No. 1, Pages 11-96
https://jamanetwork.com/journals/jama/currentissue

 

Original Investigation
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsA Randomized Clinical Trial
Nawal Al Kaabi, MBBS; Yuntao Zhang, PhD; Shengli Xia, BSc; et al.
free access has active quiz
JAMA. 2021;326(1):35-45. doi:10.1001/jama.2021.8565
This interim analysis of an ongoing randomized trial evaluates the efficacy of 2 inactivated coronavirus vaccines for preventing symptomatic COVID-19 in healthy adults and adverse events after immunization.

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesA Randomized Clinical Trial

JAMA
July 6, 2021, Vol 326, No. 1, Pages 11-96
https://jamanetwork.com/journals/jama/currentissue

 

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesA Randomized Clinical Trial
Myron S. Cohen, MD; Ajay Nirula, MD, PhD; Mark J. Mulligan, MD; et al.
free access has active quiz
JAMA. 2021;326(1):46-55. doi:10.1001/jama.2021.8828
This randomized clinical trial assesses the effect of a single intravenous infusion of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.

COVID-19 Vaccination of Health Care Personnel as a Condition of EmploymentA Logical Addition to Institutional Safety Programs

JAMA
July 6, 2021, Vol 326, No. 1, Pages 11-96
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
COVID-19 Vaccination of Health Care Personnel as a Condition of EmploymentA Logical Addition to Institutional Safety Programs
Thomas R. Talbot, MD, MPH
free access has active quiz
JAMA. 2021;326(1):23-24. doi:10.1001/jama.2021.8901
This Viewpoint uses requirements for health care worker (HCW) influenza vaccination as a condition of employment to consider whether HCW COVID-19 vaccination should be mandated as a component of patient and health care safety.

Mandatory SARS-CoV-2 Vaccinations in K-12 Schools, Colleges/Universities, and Businesses

JAMA
July 6, 2021, Vol 326, No. 1, Pages 11-96
https://jamanetwork.com/journals/jama/currentissue

 

Mandatory SARS-CoV-2 Vaccinations in K-12 Schools, Colleges/Universities, and Businesses
Lawrence O. Gostin, JD; Jana Shaw, MD, MPH; Daniel A. Salmon, PhD, MPH
free access has active quiz
JAMA. 2021;326(1):25-26. doi:10.1001/jama.2021.9342
This Viewpoint examines the epidemiologic, public health, and legal considerations for mandatory SARS-CoV-2 vaccinations in primary and secondary schools, colleges/universities, and businesses in the US.

Overview of the Issue

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 2, May 2021 Supplement
https://muse.jhu.edu/issue/44396

 

Table of Contents
Overview of the Issue
Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark
…The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.
This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care…

Trends of the global, regional and national incidence of malaria in 204 countries from 1990 to 2019 and implications for malaria prevention

Journal of Travel Medicine
Volume 28, Issue 5, July 2021
https://academic.oup.com/jtm/issue

 

Original Articles
Trends of the global, regional and national incidence of malaria in 204 countries from 1990 to 2019 and implications for malaria prevention
Qiao Liu, MD, Wenzhan Jing, PhD Candidate, Liangyu Kang, MD, Jue Liu, Min Liu

COVID-19 in Latin America—emergency and opportunity

The Lancet
Jul 10, 2021 Volume 398 Number 10295 p93-184
https://www.thelancet.com/journals/lancet/issue/current

 

Editorial
COVID-19 in Latin America—emergency and opportunity
The Lancet
Latin America and the Caribbean (LAC) have been hit the hardest by the COVID-19 pandemic, with 25% of recent global infections occurring in the region. Of the top ten countries with the highest death rate globally, eight are from LAC. The deaths from COVID-19 in the region stand at nearly 1.3 million people, but the pandemic will continue to drive excess mortality because of disrupted health services, economic instability, and deepening of existing inequalities. In addition, countries with high levels of infection can result in the emergence of more transmissible and vaccine-resistant variants. The region has not garnered global attention and now it faces new challenges that will likely worsen the situation and pose a threat to the rest of the world.

The relentlessness of the pandemic is exhausting public health interventions to contain viral spread in LAC countries, which are highly populated and have informal economies. Despite the persistent political instability in the region, the pandemic has further increased the frustration over entrenched inequities and corruption, and countries such as Peru and Brazil are currently facing civil unrest. There is distrust in governments, and more alarmingly, a widespread absence of social cohesion in the region, which hampers compliance to public health measures. Concomitantly, several variants are spreading in the region. The well known variant of concern, gamma (P.1), initially found in Brazil, has now spread to neighbouring countries and has become dominant in Uruguay. Lambda (C.37), first detected in Peru and currently considered a variant of interest, now makes up 80% of infections in Peru. More worryingly, the highly transmissible delta (B.1.617.2) variant now spreading in Europe has also been detected in at least 16 countries in LAC and there is already community transmission.

Mass vaccination is urgently required. However, only 11% of the entire population of LAC have been fully vaccinated, and although Chile has achieved a vaccination rate of more than 65%, in other countries such as Honduras and Guatemala it is less than 1%. LAC has an impressive track record in existing vaccination programmes, with low vaccine hesitancy. The bottleneck with the COVID-19 vaccine is a major limiting factor. Confronted with the global shortage, individual countries have little influence or will to secure vaccines. Less wealthy countries such as Colombia and Paraguay are relying on COVAX. But vaccine delivery to LAC is too slow to control the high infection and death rates. Regardless, COVAX distributes doses until all countries reach a 20% vaccination rate, independent of their existing epidemiology. There are also bilateral donations, but mostly driven by geopolitical motivations. Vaccines should be prioritised for the most affected countries with lower vaccination rates in LAC.

Presently, LAC urgently needs the global community to help control the pandemic in the region, but that should not stop the region from building internal capacity to manage the pandemic. Expanding local vaccine manufacturing to other countries besides Brazil and replicating COVID-19 vaccine hubs such as the one established by the South Africa consortium supported by WHO would be a start. Genome sequencing, which is essential to monitor the surge and spread of different variants, is scarcely available in the region, but PAHO has set up the COVID-19 Genomic Surveillance Regional Network to strengthen the genome sequencing capacity. According to researchers in the region, recovery and pandemic preparedness requires countries to become more self-sufficient in the production of vaccines, tests, personal protective equipment, and genome sequencing.Given the persistent political instability and poor leadership in some countries in LAC, the region would benefit from non-governmental leadership led by civil-society organisations or professional groups to push for the right to health and hold governments accountable.

Strong collaboration of countries in the region is needed and has failed catastrophically so far. In Oct, 2020, Foreign Affairs Ministers from the region signed a declaration calling for solidarity, multilateralism, and international cooperation, which has yet to be actioned. Prompted by flaws in the pandemic response, the inter-American dialogue, a network of global leaders launched a health task force, which is due to publish a White Paper in July to improve cooperation in future health emergencies in LAC. Region-led initiatives could have the potential for lasting change by developing health programmes and technological infrastructures to increase resilience and equity. The current dire situation in LAC should prompt serious reflection about the failings of regional entities such as PAHO. A much better co-ordinated response across the region is urgently needed.

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

The Lancet
Jul 10, 2021 Volume 398 Number 10295 p93-184
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Alberto M Borobia, et al. on behalf of the CombiVacS Study Group
Background
To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).
Methods
We did a phase 2, open-label, randomised, controlled trial on adults aged 18–60 years, vaccinated with a single dose of ChAdOx1-S 8–12 weeks before screening, and no history of SARS-CoV-2 infection. Participants were randomly assigned (2:1) to receive either BNT162b2 (0·3 mL) via a single intramuscular injection (intervention group) or continue observation (control group). The primary outcome was 14-day immunogenicity, measured by immunoassays for SARS-CoV-2 trimeric spike protein and receptor binding domain (RBD). Antibody functionality was assessed using a pseudovirus neutralisation assay, and cellular immune response using an interferon-γ immunoassay. The safety outcome was 7-day reactogenicity, measured as solicited local and systemic adverse events. The primary analysis included all participants who received at least one dose of BNT162b2 and who had at least one efficacy evaluation after baseline. The safety analysis included all participants who received BNT162b2. This study is registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739), and is ongoing.
Findings
Between April 24 and 30, 2021, 676 individuals were enrolled and randomly assigned to either the intervention group (n=450) or control group (n=226) at five university hospitals in Spain (mean age 44 years [SD 9]; 382 [57%] women and 294 [43%] men). 663 (98%) participants (n=441 intervention, n=222 control) completed the study up to day 14. In the intervention group, geometric mean titres of RBD antibodies increased from 71·46 BAU/mL (95% CI 59·84–85·33) at baseline to 7756·68 BAU/mL (7371·53–8161·96) at day 14 (p<0·0001). IgG against trimeric spike protein increased from 98·40 BAU/mL (95% CI 85·69–112·99) to 3684·87 BAU/mL (3429·87–3958·83). The interventional:control ratio was 77·69 (95% CI 59·57–101·32) for RBD protein and 36·41 (29·31–45·23) for trimeric spike protein IgG. Reactions were mild (n=1210 [68%]) or moderate (n=530 [30%]), with injection site pain (n=395 [88%]), induration (n=159 [35%]), headache (n=199 [44%]), and myalgia (n=194 [43%]) the most commonly reported adverse events. No serious adverse events were reported. Interpretation
BNT162b2 given as a second dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile.

Human data

Nature
Volume 595 Issue 7866, 8 July 2021
https://www.nature.com/nature/volumes/595/issues/7866

 

Human data
Computational social science is a burgeoning field of research that uses analysis of huge data sets to tackle social questions. Digital devices now give real-time access to a wealth of information on our movements, purchases and social interactions online — information that offers unprecedented power to track trends, make predictions and inform decisions. In a special issue this week, Nature probes the possibilities of — and challenges faced by — this growing field. From modelling the dynamics of infectious disease to assessing potential bias in data sets, researchers face huge opportunities to answer key societal questions — as long as they can also maintain the delicate balance of ensuring the quality and privacy of the data being used.

Integrating explanation and prediction in computational social science

Nature
Volume 595 Issue 7866, 8 July 2021
https://www.nature.com/nature/volumes/595/issues/7866

 

Perspective | 30 June 2021
Integrating explanation and prediction in computational social science
The combination of computational and social sciences requires the integration of explanatory and predictive approaches into ‘integrative modelling’, according to Hofman and colleagues.
Jake M. Hofman, Duncan J. Watts, Tal Yarkoni

Meaningful measures of human society in the twenty-first century

Nature
Volume 595 Issue 7866, 8 July 2021
https://www.nature.com/nature/volumes/595/issues/7866

Special: Computational social science
Perspective | 30 June 2021

 

Meaningful measures of human society in the twenty-first century
Approaches for the management, use and analysis of large-scale behavioural datasets that were not originally intended or created for research are described.
David Lazer, Eszter Hargittai, Jason Radford

Measuring algorithmically infused societies

Nature
Volume 595 Issue 7866, 8 July 2021
https://www.nature.com/nature/volumes/595/issues/7866

\\Special: Computational social science
Perspective | 30 June 2021

 

Perspective | 30 June 2021
Measuring algorithmically infused societies
This Perspective discusses the challenges for social science practices imposed by the ubiquity of algorithms and large-scale measurement and what should—and should not—be measured in societies pervaded by algorithms.
Claudia Wagner, Markus Strohmaier, Tina Eliassi-Rad

Thinking clearly about social aspects of infectious disease transmission

Nature
Volume 595 Issue 7866, 8 July 2021
https://www.nature.

Special: Computational social science
Perspective | 30 June 2021

 

Perspective | 30 June 2021
Thinking clearly about social aspects of infectious disease transmission
The use of new datastreams and local knowledge to shed light on social aspects of disease transmission will allow more accurate modelling and prediction of epidemics.
Caroline Buckee, Abdisalan Noor, Lisa Sattenspiel

Human social sensing is an untapped resource for computational social science

Nature
Volume 595 Issue 7866, 8 July 2021
https://www.nature.com/nature/volumes/595/issues/7866

Special: Computational social science
Perspective | 30 June 2021

 

Perspective | 30 June 2021
Human social sensing is an untapped resource for computational social science
The ability of people to understand the thoughts and actions of others—known as social sensing—can be combined with computational social science to advance research into human sociality.
Mirta Galesic, Wändi Bruine de Bruin, Tamara van der Does

SARS-CoV-2 Variants and VaccinesP.R. Krause and Others

New England Journal of Medicine
July 8, 2021 Vol. 385 No. 2
http://www.nejm.org/toc/nejm/medical-journal

 

Special Report
SARS-CoV-2 Variants and VaccinesP.R. Krause and Others
Abstract
Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.

Pediatric Vaccination During the COVID-19 Pandemic

Pediatrics
Vol. 148, Issue 1 1 Jul 2021
https://pediatrics.aappublications.org/

 

Articles
Pediatric Vaccination During the COVID-19 Pandemic
Bradley K. Ackerson, Lina S. Sy, Sungching C. Glenn, Lei Qian, Claire H. Park, Robert J. Riewerts, Steven J. Jacobsen
Pediatrics, Jul 2021, 148 (1) e2020047092
Abstract
OBJECTIVES The impact of the coronavirus disease 2019 pandemic on vaccination coverage, critical to preventing vaccine-preventable diseases, has not been assessed during the reopening period.
METHODS Vaccine uptake and vaccination coverage for recommended vaccines and for measles-containing vaccines at milestone ages were assessed in a large cohort of children aged 0 to 18 years in Southern California during January to August 2020 and were compared with those in the same period in 2019. Differences in vaccine uptake and vaccination coverage (recommended vaccines and measles-containing vaccines) in prepandemic (January to March), stay-at-home (April to May), and reopening (June to August) periods in 2020 and 2019 were compared.
RESULTS Total and measles-containing vaccine uptake declined markedly in all children during the pandemic period in 2020 compared with 2019, but recovered in children aged 0 to 23 months. Among children aged 2 to 18 years, measles-containing vaccine uptake recovered, but total vaccine uptake remained lower. Vaccination coverage (recommended and measles-containing vaccines) declined and remained reduced among most milestone age cohorts ≤24 months during the pandemic period, whereas recommended vaccination coverage in older children decreased during the reopening period in 2020 compared with 2019.
CONCLUSIONS Pediatric vaccine uptake decreased dramatically during the pandemic, resulting in decreased vaccination coverage that persisted or worsened among several age cohorts during the reopening period. Additional strategies, including immunization tracking, reminders, and recall for needed vaccinations, particularly during virtual visits, will be required to increase vaccine uptake and vaccination coverage and reduce the risk of outbreaks of vaccine-preventable diseases.